Mutual of America Capital Management LLC Sells 539 Shares of Catalent, Inc. (NYSE:CTLT)

Mutual of America Capital Management LLC lessened its position in shares of Catalent, Inc. (NYSE:CTLT) by 2.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 22,257 shares of the company’s stock after selling 539 shares during the period. Mutual of America Capital Management LLC’s holdings in Catalent were worth $1,348,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of CTLT. Nisa Investment Advisors LLC increased its stake in shares of Catalent by 1.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock valued at $619,000 after acquiring an additional 185 shares in the last quarter. GAMMA Investing LLC increased its stake in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Catalent by 1.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock valued at $1,179,000 after purchasing an additional 220 shares during the period. Crossmark Global Holdings Inc. boosted its position in shares of Catalent by 2.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after purchasing an additional 229 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Catalent by 3.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock valued at $432,000 after buying an additional 278 shares during the period.

Catalent Stock Up 0.4 %

Shares of NYSE:CTLT opened at $61.24 on Tuesday. The business’s 50 day moving average is $59.81 and its 200 day moving average is $58.32. Catalent, Inc. has a 12-month low of $36.74 and a 12-month high of $61.50. The stock has a market cap of $11.12 billion, a price-to-earnings ratio of -27.10, a PEG ratio of 2.42 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.10) earnings per share. On average, sell-side analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on CTLT shares. StockNews.com downgraded Catalent from a “hold” rating to a “sell” rating in a research note on Friday. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Finally, Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $63.40.

Insider Buying and Selling

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.